|
Re-PCI MB, In-segment (no., percent)
|
5 (7.9%)
|
63
|
4 (11.8%)
|
34
|
1.55a
|
(0.39; 6.19) 0.54
|
|
Re-PCI SB, In-segment (no., percent)
|
3 (4.8%)
|
63
|
3 (8.8%)
|
34
|
1.94a
|
(0.37; 10.16) 0.44
|
|
Definite stent thrombosis ( no., percent)
|
0 (0%)
|
63
|
3 (8.8%)
|
34
|
−0.088b
|
0.041c
|
|
CABG related to the target lesion (no., percent)
|
2 (3.2%)
|
63
|
0 (0%)
|
34
|
0.032a
|
0.54
|
|
TLR (no., percent)
|
10 (15.9%)
|
63
|
10 (29.4%)
|
34
|
2.21a
|
(0.81; 6.01) 0.12
|
|
PCI target vessel, non-target lesion or CABG not related to target lesion (no., percent)
|
0 (0%)
|
63
|
1 (2.9%)
|
34
|
−0.029b
|
0.35c
|
|
TVR (no., percent)
|
10 (15.9%)
|
63
|
11 (32.4%)
|
34
|
2.53a
|
(0. 95; 6.80) 0.07
|
|
Cardiac death (no., percent)
|
5 (7.9%)
|
63
|
5 (14.7%)
|
34
|
2.00a
|
(0.54; 7.47) 0.30
|
|
All MACE (no., percent)
|
15 (23.8%)
|
63
|
16 (47.1%)
|
34
|
2.84a
|
(1.17; 6.92) 0.02
|
|
PCI non-target vessel (no., percent)
|
6 (9.5%)
|
63
|
5 (14.7%)
|
34
|
1.64a
|
(0.46; 5.82) 0.45
|
|
Diagnostic cardiac catheterization without PCI (no., percent)
|
3 (4.8%)
|
63
|
2 (5.9%)
|
34
|
1.25a
|
(0.20; 7.87) 0.81
|
|
Non-cardiac death (no., percent)
|
2 (3.2%)
|
63
|
0 (0%)
|
34
|
0.032b
|
0.54c
|
|
Lost of follow-up (no., percent)
|
1 (1.6%)
|
64
|
0 (0%)
|
34
|
−0.016b
|
1.00c
|
|
Follow-up duration, months (mean, range, SD)
|
14.1 (0–41; 13.1)
|
63
|
12.3 (1–46; 12.8)
|
34
|
1.79b
|
(−3.70; 7.27) 0.52
|
